Study:
A Phase II Study Of Rituximab And ICE Chemotherapy In Children With Recurrent/Refractory B-Cell (CD20+) Non-Hodgkin Lymphoma And B-Cell Acute Lymphoblastic Leukemia
Rationale:
Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in
different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal
antibodies such as rituximab can locate cancer cells and either kill them or deliver
cancer-killing substances to them without harming normal cells. Combining ifosfamide,
carboplatin, and etoposide with rituximab may kill more cancer cells.
Purpose:
This phase II trial is studying how well rituximab together with ifosfamide,
carboplatin, and etoposide works in treating young patients with recurrent or refractory
non-Hodgkin`s lymphoma or acute lymphoblastic leukemia.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Leukemia
Lymphoma |
Biological: filgrastim
Biological: rituximab
Drug: carboplatin
Drug: cytarabine
Drug: etoposide
Drug: ifosfamide
Drug: methotrexate |
Phase 2 |
Verified by
Children`s Oncology Group
November, 2010
Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00058461
Study Type: Interventional
Study Design: Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-5217
United States
Timothy C. Griffin, MD., Study Chair